1-20 of 39
Robert L. Redner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Uma Borate, Rina Li Welkie, Ying Huang, Ronan T. Swords, Elie Traer, Eytan M. Stein, Tara L. Lin, Yazan F Madanat, Prapti A. Patel, Robert H. Collins, Maria R. Baer, Vu H. Duong, William Blum, Martha L. Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor J. Kovacsovics, Michael W. Deininger, Joshua F Zeidner, Rebecca Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily K Curran, Kristin L Koenig, Nyla A. Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja Gullen Marcus, Leonard Rosenberg, Brian J. Druker, Ross L Levine, Amy Burd, Ashley Owen Yocum, Alice Mims, John C. Byrd
Journal: Blood
Blood (2024) 144 (Supplement 1): 1564.
https://doi.org/10.1182/blood-2024-211261
Published: 2024
Journal Articles

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Selina Luger, Li Chen, Keith W. Pratz, Sanam Loghavi, Alexander E. Perl, Jessica K. Altman, Robert L. Redner, Amir T. Fathi, Ayman Qasrawi, Adam S. Asch, Deepa Jeyakumar, James M. Foran, Mithun V Shah, Jonathan E Kolitz, Ellin Berman, Lindsay Wilde, Sameem Abedin, Vamsi K. Kota, Krishna Gundabolu, Kristen M. O'Dwyer, Emily K Curran, Ashwin Kishtagari, Kelly Ross, Zhuoxin Sun, Mark R. Litzow
Journal: Blood
Blood (2024) 144 (Supplement 1): 221.
https://doi.org/10.1182/blood-2024-201595
Published: 2024
Journal Articles

IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T. Swords, Elie Traer, Eytan M. Stein, Tara L. Lin, Prapti A. Patel, Robert H. Collins, Maria R. Baer, Vu H. Duong, William Blum, Martha L. Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor J. Kovacsovics, Michael W. Deininger, Joshua F Zeidner, Rebecca Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily K Curran, Kristin L Koenig, Nyla A. Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja Gullen Marcus, Leonard Rosenberg, Brian J. Druker, Ross L Levine, Amy Burd, Ashley Owen Yocum, Uma Borate, Alice Mims, John C. Byrd, Yazan F. Madanat
Journal: Blood
Blood (2024) 144 (Supplement 1): 4325.
https://doi.org/10.1182/blood-2024-202596
Published: 2024
Journal Articles

Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

Uma Borate, Ying Huang, Rina Li Welkie, Ronan T. Swords, Elie Traer, Eytan M. Stein, Tara L. Lin, Yazan F Madanat, Prapti A. Patel, Robert H. Collins, Maria R. Baer, Vu H. Duong, William Blum, Martha L. Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor J. Kovacsovics, Michael W. Deininger, Joshua F Zeidner, Rebecca Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily K Curran, Kristin L Koenig, Nyla A. Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja Gullen Marcus, Leonard Rosenberg, Brian J. Druker, Ross L Levine, Amy Burd, Ashley Owen Yocum, Alice Mims, John C. Byrd
Journal: Blood
Blood (2024) 144 (Supplement 1): 4324.
https://doi.org/10.1182/blood-2024-211178
Published: 2024
Journal Articles

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T. Swords, Elie Traer, Eytan M. Stein, Tara L Lin, Prapti A. Patel, Robert H. Collins, Maria R. Baer, Vu H. Duong, William Blum, Martha Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor J. Kovacsovics, Michael W. Deininger, Joshua F. Zeidner, Rebecca Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily K Curran, Kristin L Koenig, Nyla A. Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja Gullen Marcus, Leonard Rosenberg, Brian J. Druker, Ross L Levine, Amy Burd, Ashley Owen Yocum, Uma M. Borate, Alice Mims, John C. Byrd, Yazan F. Madanat
Journal: Blood
Blood (2023) 142 (Supplement 1): 4296.
https://doi.org/10.1182/blood-2023-187044
Published: 2023
Journal Articles

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

Uma M. Borate, Ying Huang, Rina Li Welkie, Ronan T. Swords, Elie Traer, Eytan M. Stein, Tara L Lin, Yazan F. Madanat, Prapti A. Patel, Robert H. Collins, Maria R. Baer, Vu H. Duong, William Blum, Martha Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor J. Kovacsovics, Michael W. Deininger, Joshua F. Zeidner, Rebecca Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily K Curran, Kristin L Koenig, Nyla A. Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja Gullen Marcus, Leonard Rosenberg, Brian J. Druker, Ross L Levine, Amy Burd, Ashley Owen Yocum, Alice Mims, John C. Byrd
Journal: Blood
Blood (2023) 142 (Supplement 1): 4332.
https://doi.org/10.1182/blood-2023-181886
Published: 2023
Journal Articles

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Uma M. Borate, Ying Huang, Mary F. Johnson, Joshua F. Zeidner, Ronan T. Swords, Kristin L Koenig, Eytan M. Stein, Maria R. Baer, Wendy Stock, Yazan F. Madanat, Rebecca Olin, William Blum, Gary J. Schiller, Tara L Lin, Robert L. Redner, Emily K Curran, Nyla A. Heerema, Molly Martycz, Leonard Rosenberg, Sonja Gullen Marcus, Timothy Chen, Mona Stefanos, Ross L Levine, Brian J. Druker, Ashley Owen Yocum, Amy Burd, Alice Mims, John C. Byrd
Journal: Blood
Blood (2023) 142 (Supplement 1): 1535.
https://doi.org/10.1182/blood-2023-187383
Published: 2023
Journal Articles

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

Qiuying (Selina) Liu, Rina Li Welkie, Ying Huang, Ronan T. Swords, Tara L Lin, Kristin L Koenig, Yazan F. Madanat, Prapti A. Patel, Robert H. Collins, William Blum, Martha Arellano, Maria R. Baer, Wendy Stock, Tibor J. Kovacsovics, Rebecca Olin, Emily K Curran, Eytan M. Stein, Gary J. Schiller, Joshua F. Zeidner, Robert L. Redner, Nyla A. Heerema, Molly Martycz, Leonard Rosenberg, Sonja Gullen Marcus, Timothy Chen, Mona Stefanos, Ross L Levine, Brian J. Druker, Ashley Owen Yocum, Amy Burd, Alice Mims, Uma M. Borate, John C. Byrd, Elie Traer
Journal: Blood
Blood (2023) 142 (Supplement 1): 5933.
https://doi.org/10.1182/blood-2023-179609
Published: 2023
Journal Articles

Iadademstat and Gilteritinib for the Treatment of FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia: The Frida Study

Amir T. Fathi, Theodore P Braun, Alexander Joseph Ambinder, Gautam Borthakur, Robert L. Redner, Mabel Arevalo, Sonia Gutierrez, Ana Limon, Douglas V. Faller
Journal: Blood
Blood (2023) 142 (Supplement 1): 5974.
https://doi.org/10.1182/blood-2023-189291
Published: 2023
Journal Articles

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Uma Borate, Rui Li, Ying Huang, Ronan T. Swords, Elie Traer, Eytan Stein, James M. Foran, Maria R. Baer, Vu H. Duong, Wendy Stock, Olatoyosi Odenike, Prapti Patel, Robert H. Collins, Yazan F. Madanat, Tibor Kovacsovics, Michael W. Deininger, Catherine Smith, Rebecca L. Olin, Martha L. Arellano, William G. Blum, Gary J. Schiller, Tara L. Lin, Matthew C. Foster, Michael M. Boyiadzis, Robert L. Redner, Zeina Al-Mansour, Emily K Curran, Nyla A. Heerema, Theophilus J Gana, Molly Martycz, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Franchesca Druggan, Amy Burd, Ross L. Levine, Brian J. Druker, John C. Byrd, Alice S. Mims
Journal: Blood
Blood (2022) 140 (Supplement 1): 6200–6203.
https://doi.org/10.1182/blood-2022-167316
Published: 2022
Journal Articles

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Joshua F. Zeidner, Matthew C. Foster, Mary Johnson, Ying Huang, Ronan T. Swords, Eytan Stein, James M. Foran, Maria R. Baer, Wendy Stock, Yazan F. Madanat, Tibor Kovacsovics, Rebecca L. Olin, William G. Blum, Gary J. Schiller, Tara L. Lin, Robert L. Redner, Zeina Al-Mansour, Emily K Curran, Nyla A. Heerema, Molly Martycz, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Franchesca Druggan, Amy Burd, Ross L. Levine, Brian J. Druker, Uma Borate, John C. Byrd, Alice S. Mims
Journal: Blood
Blood (2022) 140 (Supplement 1): 9070–9073.
https://doi.org/10.1182/blood-2022-166715
Published: 2022
Journal Articles

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1 st Induction Regimen

Konstantinos Lontos, Robert L. Redner, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic J. Farah, Annie Im, Kathleen Dorritie, Alison R. Sehgal, James M. Rossetti, Daniel Normolle, Michael M. Boyiadzis
Journal: Blood
Blood (2022) 140 (Supplement 1): 6145–6146.
https://doi.org/10.1182/blood-2022-156468
Published: 2022
Journal Articles

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Prapti Patel, Amy S. Ruppert, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Michael M. Boyiadzis, Ronan Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley Owen Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Alice S. Mims
Journal: Blood
Blood (2021) 138 (Supplement 1): 875.
https://doi.org/10.1182/blood-2021-149115
Published: 2021
Journal Articles

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Elie Traer, Ying Huang, Alice S. Mims, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti Patel, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Michael M. Boyiadzis, Ronan Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley O. Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Uma Borate
Journal: Blood
Blood (2021) 138 (Supplement 1): 1277.
https://doi.org/10.1182/blood-2021-148207
Published: 2021
Journal Articles

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Vu H. Duong, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Ronan T. Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley O. Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Michael M. Boyiadzis
Journal: Blood
Blood (2021) 138 (Supplement 1): 1279.
https://doi.org/10.1182/blood-2021-151234
Published: 2021
Journal Articles

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Anastasia Tsagianni, MD, Konstantinos Lontos, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic J. Farah, MD, Robert L. Redner, MD, Annie Im, MD, Kathleen A. Dorritie, MD, Alison R. Sehgal, MD, James M. Rossetti, DO, Melissa Saul, MS, William Gooding, MS, Michael Boyiadzis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
https://doi.org/10.1182/blood-2020-138561
Published: 2020
Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Rachel J. Cook, MD, Tamara Moyo, MD PhD, Jane L. Liesveld, MD, David A. Rizzieri, MD, Eytan M. Stein, MD, Stephane De Botton, MD PhD, Gail J. Roboz, MD, Mikkael A. Sekeres, MD MS, Joseph G. Jurcic, MD, Azra Raza, MD, Robert L. Redner, MD, Dale L. Bixby, MD PhD, Jorge E. Cortes, MD, Kristin Stephens, Angela Volkert, Qing Kang, PhD, Emmanuelle Di Tomaso, PhD, David A. Roth, MD, Carlos E Vigil, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2735.
https://doi.org/10.1182/blood-2018-99-111285
Published: 2018
Journal Articles

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Asha Ricciuti, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, James M. Rossetti, DO, Yongli Shuai, PhD, Daniel Normolle, PhD, Rahim Remtulla, MD, Shawn Tahata, MD, Michael Boyiadzis, MD, Annie Im, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4000.
https://doi.org/10.1182/blood-2018-99-113935
Published: 2018
Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

Joseph G. Jurcic, MD, Azra Raza, MD, George Vlad, PhD, Eytan M. Stein, MD, Mikhail Roshal, MDPhD, Dale L. Bixby, Daniel F. Boyer, MD PhD, Carlos Enrique Vigil, MD, Sergei Syrbu, MD PhD, Mikkael A. Sekeres, MD MS, Heesun J. Rogers, MD PhD, David A. Rizzieri, MD, Anand Shreeram Lagoo, MD PhD, Gail J. Roboz, MD, Robert L. Redner, MD, David P. Steensma, MD, Rachel J. Cook, MD, Tamara Moyo, MD PhD, Michael McKeown, PhD, Nigel J. Waters, PhD, Kristin Stephens, Angela Volkert, Emmanuelle Di Tomaso, PhD, David A. Roth, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2633.
https://doi.org/10.1182/blood.V130.Suppl_1.2633.2633
Published: 2017
Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Michael Boyiadzis, MD MHSc, Mounzer Agha, MD, Robert L Redner, MD, Alison Sehgal, MD, Annie Im, MD, Jing-Zhou Hou, Rafic Farah, MD, Kathleen A. Dorritie, MD, Anastasios Raptis, MD PhD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Hans Klingemann, MD PhD, Hong Wang, PhD, Natalia Lapteva, PhD, Mei Zhuyong, MD, Lisa H Butterfield, PhD, Cliona M. Rooney, PhD, Theresa L Whiteside, PhD
Journal: Blood
Blood (2016) 128 (22): 1649.
https://doi.org/10.1182/blood.V128.22.1649.1649
Published: 2016